Delivering breakthrough vaccines, specialty medicines and trusted general medicines to patients in over 150 countries.
From prevention through world-leading vaccines to treatment with innovative specialty medicines, GSK's portfolio spans every stage of the patient journey. Our commitment is to bring differentiated, high-quality medicines to people who need them β backed by robust scientific evidence and a relentless focus on patient outcomes.
World-leading portfolio protecting against RSV, shingles, meningitis and hepatitis across all ages.
Targeted oncology, immunology and HIV treatments through ViiV Healthcare, advancing precision care.
Trusted respiratory inhalers like Ventolin and essential antibiotics supporting patients globally every day.
GSK is one of the world's largest vaccine companies, with a portfolio that spans infectious diseases affecting people of all ages. Our vaccines help prevent illnesses such as RSV in older adults, shingles, meningococcal disease, hepatitis A and B, and influenza. We are pioneers in adjuvant technology β our proprietary AS01 and AS04 adjuvant systems enhance immune responses and enable protection where traditional approaches fall short.
Our recently approved RSV vaccine, Arexvy, represents a major milestone: the world's first RSV vaccine for adults aged 60 and over. With respiratory syncytial virus hospitalising hundreds of thousands of older adults each year, this innovation addresses a significant unmet medical need. We continue to invest in next-generation vaccine technologies, including our mRNA and self-amplifying RNA platforms, to stay ahead of emerging infectious threats.
Our specialty medicines portfolio focuses on areas where we can make the greatest difference for patients with serious and complex conditions. In oncology, we are developing antibody-drug conjugates and novel immunotherapies targeting difficult-to-treat cancers. Blenrep, our anti-BCMA therapy, represents our commitment to transforming outcomes for patients with multiple myeloma.
In immunology, Benlysta remains the only biologic specifically approved for systemic lupus erythematosus and lupus nephritis β conditions that disproportionately affect women of colour. Through our majority stake in ViiV Healthcare, we are also a global leader in HIV treatment. Cabenuva, the first long-acting injectable regimen for HIV, has transformed how people living with HIV manage their condition β replacing daily pills with monthly or bi-monthly injections.
Over 70 potential new medicines and vaccines in clinical development β powered by genetics, AI and immune science.
Our pipeline spans infectious diseases, oncology, immunology and respiratory medicine. With a disciplined approach to R&D investment, we prioritise programmes with the greatest potential to deliver both patient impact and strong returns.